Health
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021 – StreetInsider.com
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition Pan-cancer anti-tumor activity, including in tumors exposed to prior lines…
April 10, 2021 8:30 AM EDT
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premiumhere.
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition
Pan-cancer anti-tumor activity, including in tumors exposed to prior lines of therapy, seen with intermittent dosing of KB-0742
Initial safety, pharmacokinetic and pharmacodynamic data from the ongoing Phase 1/2 clinical trial for KB-0742 expected in fourth quarter…
-
General21 hours agoAustralian economy still vulnerable to US bond turmoil
-
General7 hours agoDemocratic senators want an investigation into potential market manipulation from Trump’s inner circle
-
Business17 hours agoWhat I’d buy before the ASX rebounds: 3 high-conviction share picks
-
Noosa News6 hours agoMotorbike rider dies after car collision at Kidaman Creek, west of Sunshine Coast